Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others), by Route of Administration (Oral, Intravenous, and Topical), by Distribution Channel (Hospital Pharmac

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others), by Route of Administration (Oral, Intravenous, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.
Market Dynamics
Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2022, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.
Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-γ, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.
Key features of the study:
This report provides an in-depth analysis of global acute vulvovaginal candidiasis treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market
Detailed Segmentation:
Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
Oral
Intravenous
Topical
Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region:
North America
By Country
U.S.
Canada
By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Route of Administration
Oral
Intravenous
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Mycovia Pharmaceuticals, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Scynexis, Inc.
Basilea Pharmaceutica Ltd.
Astellas Pharma Inc.
Grupo Ferrer Internacional, S.A.
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc.
Cidara Therapeutics, Inc.
Amplyx Pharmaceuticals Inc.
Pfizer, Inc.
“*” marked represents similar segmentation in other categories in the respective section.